Top

Breast Cancer

Published in:

01-07-2017 | Special Feature

Controversies in the role of postmastectomy radiotherapy in breast cancer patients with one to three positive axillary nodes and safety of integrating radiotherapy and breast reconstruction

Author: Kenji Sekiguchi

Published in: Breast Cancer | Issue 4/2017

Excerpt

In this special feature, readers will find four articles related to postmastectomy radiotherapy (PMRT). …

EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383:2127–35.

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26:1533–46.CrossRefPubMedPubMedCentral

Yamauchi C, Komoike Y, Tsugawa K, Yotsumoto D, Wada N, Sugae S, et al. Questionnaire survey of axillary surgery and radiation therapy for breast cancer in Japan. The 28th Annual Meeting of the Japanese Society for Radiation Oncology. 2015.

Ishikawa T, Kaise H, Yamada K, Hosonaga M, Chishima T, Narui K, et al. Objection to postoperative radiation therapy in breast cancer with one to three lymph nodes involvements. Breast Cancer. 2017. doi:10.1007/s12282-016-0749-5.

Tada K, Nishioka K, Kikuchi Y, Niwa T, Seto Y. Postmastectomy radiation therapy in breast cancer with 1–3 involved lymph nodes: the Pros. Breast Cancer. 2017. doi:10.1007/s12282-017-0787-7.

Poortmans P. Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate. Lancet. 2014;383:2104–6.CrossRefPubMed

Harris JR. Fifty years of progress in radiation therapy for breast cancer. Am Soc Clin Oncol Educ Book. 2014;21–5.

Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373:307–16.CrossRefPubMedPubMedCentral

Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 2015;373:317–27.CrossRefPubMed

10.

Thorsen LB, Offersen BV, Dano H, Berg M, Jensen I, Pedersen AN, et al. DBCG-IMN: a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer. J Clin Oncol. 2016;34:314–20.CrossRefPubMed

11.

Recht A, Comen EA, Fine RE, Fleming GF, Hardenbergh PH, Ho AY, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. J Clin Oncol. 2016;34:4431–42.CrossRefPubMed

12.

Kunkler IH, Canney P, van Tienhoven G, Russell NS. Elucidating the role of chest wall irradiation in ‘intermediate-risk’ breast cancer: the MRC/EORTC SUPREMO trial. Clin Oncol (R Coll Radiol). 2008;20:31–4.CrossRef

13.

Sekiguchi K, Kawamori J, Yamauchi H. Breast reconstruction and postmastectomy radiotherapy: complications by type and timing and other problems in radiation oncology. Breast Cancer. 2017. doi:10.1007/s12282-017-0754-3.

14.

Terao Y, Taniguchi K, Fujii M, Moriyama S. Postmastectomy radiation therapy and breast reconstruction with autologous tissue. Breast Cancer. 2017;91. doi:10.1007/s12282-017-0760-5.

15.

Jagsi R, Momoh AO, Qi J, Hamill JB, Bilig J, Kim HM, et al. Impact of radiotherapy on complications and patient-reported outcomes after breast reconstruction: Findings from the prospective multicenter MROC study. San Antonio Breast Cancer Symposium. 2016.

Title: Controversies in the role of postmastectomy radiotherapy in breast cancer patients with one to three positive axillary nodes and safety of integrating radiotherapy and breast reconstruction
Author: Kenji Sekiguchi
Publication date: 01-07-2017
Publisher: Springer Japan
Published in: Breast Cancer / Issue 4/2017
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-017-0788-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2017

NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer

The effects of complex exercise on shoulder range of motion and pain for women with breast cancer-related lymphedema: a single-blind, randomized controlled trial

Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer

Atypical femoral fracture after receiving antiresorptive drugs in breast cancer patients with bone metastasis

Long non-coding RNA TUG1 promotes cell proliferation and metastasis in human breast cancer

Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer